Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors.

Abstract:

BACKGROUND:Controversy exists as to what may be defined as standard of care (including markers for stratification) for patients with atypical teratoid/rhabdoid tumors (ATRTs). The European Rhabdoid Registry (EU-RHAB) recruits uniformly treated patients and offers standardized genetic and DNA methylation analyses. METHODS:Clinical, genetic, and treatment data of 143 patients from 13 European countries were analyzed (2009-2017). Therapy consisted of surgery, anthracycline-based induction, and either radiotherapy or high dose chemotherapy following a consensus among European experts. Fluorescence in situ hybridization, multiplex ligation-dependent probe amplification, and sequencing were employed for assessment of somatic and germline mutations in SWItch/sucrose nonfermentable related, matrix associated, actin dependent regulator of chromatin, subfamily B (SMARCB1). Molecular subgroups (ATRT-SHH, ATRT-TYR, and ATRT-MYC) were determined using DNA methylation arrays, resulting in profiles of 84 tumors. RESULTS:Median age at diagnosis of 67 girls and 76 boys was 29.5 months. Five-year overall survival (OS) and event-free survival (EFS) were 34.7 ± 4.5% and 30.5 ± 4.2%, respectively. Tumors displayed allelic partial/whole gene deletions (66%; 122/186 alleles) or single nucleotide variants (34%; 64/186 alleles) of SMARCB1. Germline mutations were detected in 26% of ATRTs (30/117). The patient cohort consisted of 47% ATRT-SHH (39/84), 33% ATRT-TYR (28/84), and 20% ATRT-MYC (17/84). Age <1 year, non-TYR signature (ATRT-SHH or -MYC), metastatic or synchronous tumors, germline mutation, incomplete remission, and omission of radiotherapy were negative prognostic factors in univariate analyses (P < 0.05). An adjusted multivariate model identified age <1 year and a non-TYR signature as independent negative predictors of OS: high risk (<1 y + non-TYR; 5-y OS = 0%), intermediate risk (<1 y + ATRT-TYR or ≥1 y + non-TYR; 5-y OS = 32.5 ± 8.7%), and standard risk (≥1 y + ATRT-TYR, 5-y OS = 71.5 ± 12.2%). CONCLUSIONS:Age and molecular subgroup status are independent risk factors for survival in children with ATRT. Our model warrants validation within future clinical trials.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Frühwald MC,Hasselblatt M,Nemes K,Bens S,Steinbügl M,Johann PD,Kerl K,Hauser P,Quiroga E,Solano-Paez P,Biassoni V,Gil-da-Costa MJ,Perek-Polnik M,van de Wetering M,Sumerauer D,Pears J,Stabell N,Holm S,Hengartner H,Ge

doi

10.1093/neuonc/noz244

subject

Has Abstract

pub_date

2020-07-07 00:00:00

pages

1006-1017

issue

7

eissn

1522-8517

issn

1523-5866

pii

5688769

journal_volume

22

pub_type

杂志文章
  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.

    abstract::This study estimated the maximum tolerated dose (MTD) of imatinib with irradiation in children with newly diagnosed brainstem gliomas, and those with recurrent malignant intracranial gliomas, stratified according to use of enzyme-inducing anticonvulsant drugs (EIACDs). In the brainstem glioma stratum, imatinib was ini...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-031

    authors: Pollack IF,Jakacki RI,Blaney SM,Hancock ML,Kieran MW,Phillips P,Kun LE,Friedman H,Packer R,Banerjee A,Geyer JR,Goldman S,Poussaint TY,Krasin MJ,Wang Y,Hayes M,Murgo A,Weiner S,Boyett JM

    更新日期:2007-04-01 00:00:00

  • A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.

    abstract:BACKGROUND:Both the epidermal growth factor receptor and vascular endothelial growth factor pathways are frequently overexpressed in glioblastoma multiforme. This study combined bevacizumab, a vascular endothelial growth factor inhibitor, and erlotinib, an epidermal growth factor receptor inhibitor, with standard radia...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou029

    authors: Clarke JL,Molinaro AM,Phillips JJ,Butowski NA,Chang SM,Perry A,Costello JF,DeSilva AA,Rabbitt JE,Prados MD

    更新日期:2014-07-01 00:00:00

  • Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults.

    abstract::Radiotherapy is ubiquitous in the treatment of patients with both primary brain tumors as well as disease which is metastatic to the brain. This therapy is not without cost, however, as cognitive decline is frequently associated with cranial radiation, particularly with whole brain radiotherapy (WBRT). The precise mec...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox195

    authors: Wilke C,Grosshans D,Duman J,Brown P,Li J

    更新日期:2018-04-09 00:00:00

  • Late relapse in primary central nervous system lymphoma: clonal persistence.

    abstract::Recurrence of primary central nervous system lymphoma (PCNSL) after initial diagnosis and treatment occurs within 2 years in most patients, and relapse after 5 years is rare. We evaluated late relapse in our PCNSL population. We identified 10 patients from our database of 378 patients (268 achieved a complete response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor014

    authors: Nayak L,Hedvat C,Rosenblum MK,Abrey LE,DeAngelis LM

    更新日期:2011-05-01 00:00:00

  • Prospective study of cigarette smoking and adult glioma: dosage, duration, and latency.

    abstract::Tobacco products are major contributors of exogenous N-nitroso compounds, a group of potent neurocarcinogens. Overall results from studies of smoking and brain tumors have been null, but have provided little information on duration, age at smoking initiation, and latency. We prospectively examined the relation between...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-005

    authors: Holick CN,Giovannucci EL,Rosner B,Stampfer MJ,Michaud DS

    更新日期:2007-07-01 00:00:00

  • Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.

    abstract::Glioblastoma multiforme, a highly aggressive tumor of the central nervous system, has a dismal prognosis that is due in part to its resistance to radio- and chemotherapy. The protein kinase C (PKC) family of serine threonine kinases has been implicated in the formation and proliferation of glioblastoma multiforme. Mem...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor084

    authors: Azoitei N,Kleger A,Schoo N,Thal DR,Brunner C,Pusapati GV,Filatova A,Genze F,Möller P,Acker T,Kuefer R,Van Lint J,Baust H,Adler G,Seufferlein T

    更新日期:2011-07-01 00:00:00

  • Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.

    abstract:BACKGROUND:Temporal muscle thickness (TMT) was described as a surrogate marker of skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma. METHODS:TMT was analyzed on cranial MR images of 596 patients with progression of glioblastoma after radiochemo...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1093/neuonc/noz131

    authors: Furtner J,Genbrugge E,Gorlia T,Bendszus M,Nowosielski M,Golfinopoulos V,Weller M,van den Bent MJ,Wick W,Preusser M

    更新日期:2019-12-17 00:00:00

  • Paraneoplastic chorea: case study with autopsy confirmation.

    abstract::A 67-year-old man presented with a 7-month history of insidiously progressive chorea, ataxia, and vertigo. Neurologic examination revealed deficits referable to the basal nuclei, cerebellar vermis, and vestibular nuclei. Small-cell lung cancer was diagnosed by fine-needle biopsy of a parahilar mass. After chemotherapy...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/4.3.192

    authors: Tremont-Lukats IW,Fuller GN,Ribalta T,Giglio P,Groves MD

    更新日期:2002-07-01 00:00:00

  • Copy number profiling across glioblastoma populations has implications for clinical trial design.

    abstract:Background:Copy number alterations form prognostic molecular subtypes of glioblastoma with clear differences in median overall survival. In this study, we leverage molecular data from several glioblastoma cohorts to define the distribution of copy number subtypes across random cohorts as well as cohorts with selection ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy108

    authors: Cimino PJ,McFerrin L,Wirsching HG,Arora S,Bolouri H,Rabadan R,Weller M,Holland EC

    更新日期:2018-09-03 00:00:00

  • Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.

    abstract:BACKGROUND:The standard of care for newly diagnosed glioblastoma is maximal safe surgical resection, followed by chemoradiation therapy. We assessed carmustine wafer implantation efficacy and safety when used in combination with standard care. METHODS:Included were adult patients with (n = 354, implantation group) and...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1093/neuonc/nov126

    authors: Pallud J,Audureau E,Noel G,Corns R,Lechapt-Zalcman E,Duntze J,Pavlov V,Guyotat J,Hieu PD,Le Reste PJ,Faillot T,Litre CF,Desse N,Petit A,Emery E,Voirin J,Peltier J,Caire F,Vignes JR,Barat JL,Langlois O,Dezamis E

    更新日期:2015-12-01 00:00:00

  • Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

    abstract::Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression. We evaluated 56 patients with recurrent brain tumors wh...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/5.2.89

    authors: Meyers CA,Hess KR

    更新日期:2003-04-01 00:00:00

  • Updates in the management of brain metastases.

    abstract::The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advances and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have led to better systemic control and longer overall patient survi...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/now127

    authors: Arvold ND,Lee EQ,Mehta MP,Margolin K,Alexander BM,Lin NU,Anders CK,Soffietti R,Camidge DR,Vogelbaum MA,Dunn IF,Wen PY

    更新日期:2016-08-01 00:00:00

  • Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.

    abstract:BACKGROUND:Outcomes for patients with recurrent glioblastoma multiforme (GBM) are poor and may be improved by immunotherapy. We investigated the safety and efficacy of an autologous heat-shock protein peptide complex-96 (HSPPC-96) vaccine for patients with recurrent GBM. METHODS:In this open-label, single-arm, phase I...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/not203

    authors: Bloch O,Crane CA,Fuks Y,Kaur R,Aghi MK,Berger MS,Butowski NA,Chang SM,Clarke JL,McDermott MW,Prados MD,Sloan AE,Bruce JN,Parsa AT

    更新日期:2014-01-01 00:00:00

  • In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.

    abstract::Histone modification has emerged as a promising approach to cancer therapy. We explored the in vivo efficacy of a butyric acid derivative, pivaloyloxymethyl butyrate (AN-9), for the treatment of gliomas. Relative to control and single-modality treatments, the combination of AN-9 and radiation significantly inhibited t...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-032

    authors: Entin-Meer M,Yang X,VandenBerg SR,Lamborn KR,Nudelman A,Rephaeli A,Haas-Kogan DA

    更新日期:2007-04-01 00:00:00

  • ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma.

    abstract:BACKGROUND:Targeting immune checkpoint proteins has recently gained substantial attention due to the dramatic success of this strategy in clinical trials for some cancers. Inducible T-cell co-stimulator ligand (ICOSLG) is a member of the B7 family of immune regulatory ligands, expression of which in cancer is implicate...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz204

    authors: Iwata R,Hyoung Lee J,Hayashi M,Dianzani U,Ofune K,Maruyama M,Oe S,Ito T,Hashiba T,Yoshimura K,Nonaka M,Nakano Y,Norian L,Nakano I,Asai A

    更新日期:2020-03-05 00:00:00

  • Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

    abstract:Background:Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens. Methods:We report the results of feasibility, phase I, and phase II studies of tandutinib (MLN518), an orally bioavailable inhibitor of type III...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/now185

    authors: Batchelor TT,Gerstner ER,Ye X,Desideri S,Duda DG,Peereboom D,Lesser GJ,Chowdhary S,Wen PY,Grossman S,Supko JG

    更新日期:2017-04-01 00:00:00

  • VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.

    abstract:BACKGROUND:Malignant glioma is a common and lethal primary brain tumor in adults. Here we identified a novel oncoprotein, vesicle-associated membrane protein 8 (VAMP8), and investigated its roles in tumorigenisis and chemoresistance in glioma. METHODS:The expression of gene and protein were determined by quantitative P...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou219

    authors: Chen Y,Meng D,Wang H,Sun R,Wang D,Wang S,Fan J,Zhao Y,Wang J,Yang S,Huai C,Song X,Qin R,Xu T,Yun D,Hu L,Yang J,Zhang X,Chen H,Chen J,Chen H,Lu D

    更新日期:2015-03-01 00:00:00

  • Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.

    abstract::We conducted a single-arm phase II study to evaluate the efficacy and safety of radiotherapy combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating malignant astrocytoma in children and anaplastic ependymoma in patients of all ages. Between 1984 and 199...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1093/neuonc/2.1.22

    authors: Levin VA,Lamborn K,Wara W,Davis R,Edwards M,Rabbitt J,Malec M,Prados MD

    更新日期:2000-01-01 00:00:00

  • Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

    abstract::The objective of this study was to evaluate whether longitudinal levels of serum YKL-40 correlate with disease status or survival in adults with gliomas. Patients with histologically confirmed gliomas were eligible for this longitudinal study. Serum samples were collected prospectively and concurrently with MRI scans ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor117

    authors: Iwamoto FM,Hottinger AF,Karimi S,Riedel E,Dantis J,Jahdi M,Panageas KS,Lassman AB,Abrey LE,Fleisher M,DeAngelis LM,Holland EC,Hormigo A

    更新日期:2011-11-01 00:00:00

  • Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

    abstract::Treatment of malignant gliomas represents one of the most formidable challenges in oncology. The combination of surgery, radiation, and chemotherapy yields median survivals of less than one year. Here we demonstrate the use of a minimally invasive surgical technique, convection-enhanced delivery (CED), for local admin...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-001

    authors: Saito R,Krauze MT,Noble CO,Drummond DC,Kirpotin DB,Berger MS,Park JW,Bankiewicz KS

    更新日期:2006-07-01 00:00:00

  • Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.

    abstract:BACKGROUND:No more than half of patients with neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) develop vision loss. Prospectively identifying those who will require therapy remains challenging, because no reliable factors have yet been identified that predict future vision loss. To determine wheth...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not068

    authors: de Blank PM,Berman JI,Liu GT,Roberts TP,Fisher MJ

    更新日期:2013-08-01 00:00:00

  • Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

    abstract::Antiangiogenic therapy is associated with increased radiographic responses in glioblastomas, but tumors invariably recur. Because tumor-associated macrophages have been shown to mediate escape from antiangiogenic therapy in preclinical models, we examined the role of macrophages in patients with recurrent glioblastoma...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not082

    authors: Lu-Emerson C,Snuderl M,Kirkpatrick ND,Goveia J,Davidson C,Huang Y,Riedemann L,Taylor J,Ivy P,Duda DG,Ancukiewicz M,Plotkin SR,Chi AS,Gerstner ER,Eichler AF,Dietrich J,Stemmer-Rachamimov AO,Batchelor TT,Jain RK

    更新日期:2013-08-01 00:00:00

  • Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

    abstract::Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has th...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou222

    authors: Roth P,Weller M

    更新日期:2014-10-01 00:00:00

  • Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

    abstract:Background:Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and pharmacokinetics of sonidegib in children with relapsed/recurrent tumors followed by a phase II trial in pediatric and adult patients with relapsed medulloblastoma (MB) to assess tumor response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox109

    authors: Kieran MW,Chisholm J,Casanova M,Brandes AA,Aerts I,Bouffet E,Bailey S,Leary S,MacDonald TJ,Mechinaud F,Cohen KJ,Riccardi R,Mason W,Hargrave D,Kalambakas S,Deshpande P,Tai F,Hurh E,Geoerger B

    更新日期:2017-10-19 00:00:00

  • Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey.

    abstract:BACKGROUND:More than 90% of patients with diffuse intrinsic pontine glioma (DIPG) will die within 2 years of diagnosis. Patients deteriorate rapidly during the disease course, which severely impairs their quality of life. To date, no specific research on this clinically important subject has been conducted. This study ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov250

    authors: Veldhuijzen van Zanten SE,van Meerwijk CL,Jansen MH,Twisk JW,Anderson AK,Coombes L,Breen M,Hargrave OJ,Hemsley J,Craig F,Cruz O,Kaspers GJ,van Vuurden DG,Hargrave DR,SIOPE DIPG Network.

    更新日期:2016-04-01 00:00:00

  • Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics.

    abstract:BACKGROUND:Assessment of treatment response by measuring tumor size is known to be a late and potentially confounded response index. Serial diffusion MRI has shown potential for allowing earlier and possibly more reliable response assessment in adult patients, with limited experience in clinical settings and in pediatr...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not034

    authors: Rodriguez Gutierrez D,Manita M,Jaspan T,Dineen RA,Grundy RG,Auer DP

    更新日期:2013-08-01 00:00:00

  • Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.

    abstract::Angiogenesis plays a key role in glioblastoma biology and antiangiogenic agents are under clinical investigation with promising results. However, the angiogenic profiles of patients with glioblastoma and their clinical significance are not well understood. Here we characterize the serum angiogenic profile of patients ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq170

    authors: Crocker M,Ashley S,Giddings I,Petrik V,Hardcastle A,Aherne W,Pearson A,Bell BA,Zacharoulis S,Papadopoulos MC

    更新日期:2011-01-01 00:00:00

  • Cisplatin-induced peripheral neuropathy is associated to neuronal senescence-like response.

    abstract:BACKGROUND:Cisplatin-Induced Peripheral Neuropathy (CIPN) is a frequent serious dose-dependent adverse event that can determine dosage limitations for cancer treatment. CIPN severity correlates with the amount of platinum detected in sensory neurons of the dorsal root ganglia (DRG). However, the exact pathophysiology o...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa151

    authors: Calls A,Torres-Espin A,Navarro X,Yuste VJ,Udina E,Bruna J

    更新日期:2020-06-29 00:00:00

  • Invasion patterns in brain metastases of solid cancers.

    abstract:BACKGROUND:Brain metastases are generally considered to be well demarcated from the surrounding brain parenchyma, although infiltrative growth patterns have been observed. We systemically investigated infiltration patterns and expression of adhesion molecules in a large and well-defined series of autopsy cases of brain...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not112

    authors: Berghoff AS,Rajky O,Winkler F,Bartsch R,Furtner J,Hainfellner JA,Goodman SL,Weller M,Schittenhelm J,Preusser M

    更新日期:2013-12-01 00:00:00

  • Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.

    abstract:Background:Craniopharyngiomas are neoplasms of the sellar/parasellar region that are classified into adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP) subtypes. Surgical resection of craniopharyngiomas is challenging, and recurrence is common, frequently leading to profound morbidity. BRAF ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy035

    authors: Coy S,Rashid R,Lin JR,Du Z,Donson AM,Hankinson TC,Foreman NK,Manley PE,Kieran MW,Reardon DA,Sorger PK,Santagata S

    更新日期:2018-07-05 00:00:00